Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Nakhia Impex LLC
Modality
UNKNOWN
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06444035CT.gov Extended Therapeutic Effect of 35kDa Hyaluronan Fragment Injection in Patients With Chronic Pain Caused by Myofascial Pain Syndrome | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Myofascial Pain Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| ha35 (this asset) | Nakhia Impex LLC | N/A | D · 30 |
| Granisetron | Karolinska Institutet | P4 | BB |
| Imc-1 | Innovative Med Concepts, LLC | P2 | B |
| Capsaicin | Stamford Hospital | P2 | CCC |
| Solvazinc | Cairo University | Early P1 | C |
| Prilocaine | Bursa City Hospital | N/A | D |
| Dextrose | Ankara University | Unk | D |
| Baclofen | Saint Petersburg State University, Russia | Unk | D |
| Lidocaine | Cairo University | N/A | D |
+3 more in the Myofascial Pain Syndrome cohort
Other indications for ha35
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Ulcer Of Skin | — | N/A | D · 30 |
| Cancer-Related Condition | — | N/A | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. ha35 in Myofascial Pain Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ha35-myofascial-pain-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →